

ASX/Media Release

14/08/2020

After record appointments in Australia, Emerald plans international expansion and proposes name change

Highlights

- *Month-on-month growth continues with a record 795 appointments in July, despite COVID-19*
- *Recently announced data deals demonstrate desirability of Emerald's unique Real-World Evidence (RWE) and care model in Australia, the UK and elsewhere*
- *To support Emerald's global approach to RWE and expanded offerings in remote chronic disease management, digital health technology development and COVID health screening, Emerald proposes name change to Emyria Limited*

Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence (RWE) and clinical services company intends to change its name to Emyria Limited, as part of a rebranding consistent with its global ambitions and expanded offerings. The ASX code of EMD will remain unchanged. A notice of a general meeting to approve the name change will be sent to shareholders shortly.

July saw record appointments for the Company's clinical services in Australia, while provision of the majority of health services have trended downwards, due to the COVID-19 pandemic. In response, Emerald is actively hiring clinicians to meet growing demand for its clinical services, expanding its remote monitoring capabilities and increasing its data insight platforms.

The planned name change follows the announcement on 10 August 2020 of its data collaboration with a UK partner, demonstrating the global desirability of the Company's Real-World Evidence asset and the unique care model that supports it.

"The recently announced data deal is the first step towards bringing our evidence-generating care model to international markets and we expect to build off that quickly in several geographies and across different health monitoring applications, where our Real-World Evidence asset can be utilised." said Emerald Clinics CEO Dr Michael Winlo.

"Emerald Clinics has developed a trusted brand within Australia that resonates with clinicians and patients, but as our business has evolved and as we increase engagements overseas, it has become clear that a rebrand was the best way forward to help communicate the breadth of what we do and our global aspirations."

"Emyria speaks to our mission to use a myriad of data to provide individualised care beyond the physical confines of a clinic. In this next normal, leveraging remote data capture and real-time health monitoring to improve care and deliver insights that support new treatment development will become even more critical."

Release authorised by:

Dr Michael Winlo, CEO and Managing Director

For further information:

Dr Michael Winlo
CEO
(08) 6559 2800

investors@emeraldclinics.com.au

Matt Wright
Media/investor relations
+61 (0) 451 896 420

matt@nwrcommunications.com.au

About Emerald Clinics Limited

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology. The Emerald model provides care while also co-creating high quality and ethically sourced clinical data from informed and consenting patients. Emerald's evidence is used to accelerate the development of new treatments and models of care. Emerald customers pay for deidentified data, clinical trials and consulting services or monitor their workforce.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.